PA
LXEO icon

Profund Advisors’s Lexeo Therapeutics LXEO Stock Holding History

Profund Advisors’s Portfolio LXEO Stock Details LXEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$160K Sell
34,317
-10,844
-24% -$58.7K ﹤0.01% 1121
2026
Q1 		$259K Buy
45,161
+7,107
+19% +$50.4K 0.01% 856
2025
Q4 		$378K Buy
+38,054
New +$347K 0.01% 717

Other funds holding LXEO

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Profund Advisors's LXEO Position: Q2 2026 in Review

Profund Advisors reduced its Lexeo Therapeutics (LXEO) stake by 24% in Q2 2026, selling an estimated $58.7K and leaving 34,317 shares worth $160K. The position accounts for ﹤0.01% of the portfolio, ranked #1121.

Profund Advisors first reported a position in LXEO in Q4 2025 and has held it in 3 quarters since. The position peaked at $378K in Q4 2025. 142 funds tracked by Wall St. Rank hold LXEO as of Q2 2026.

  • Profund Advisors held 34,317 shares of Lexeo Therapeutics worth $160K as of Q2 2026.
  • Profund Advisors sold 10,844 Lexeo Therapeutics shares in Q2 2026, an estimated $58.7K.
  • Lexeo Therapeutics made up ﹤0.01% of Profund Advisors's portfolio in Q2 2026, its #1121 holding.
  • Profund Advisors first reported a position in Lexeo Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Profund Advisors's Lexeo Therapeutics position peaked at $378K in Q4 2025.
  • 142 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q2 2026.

Based on Profund Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.